GC Biopharma Corp. (006280.KS) Stock
GC Biopharma Corp.

Company profile
GC Biopharma reported revenue of 1.68 trillion KRW for fiscal year 2024, up 3.3% from fiscal year 2023, and a net loss of 26.28 billion KRW. That is a net profit margin of -1.6% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 500.26 billion KRW, up 19.9% from a year before. Its largest business segment, Manufacturing and Sales of Pharmaceuticals, Etc., brought in 91% of segment revenue in fiscal year 2025; South Korea was the largest region with 71%. In Q2 2025 it reported net income of 37.99 billion KRW, against a net loss of 6.94 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 1.71 trillion KRW in fiscal year 2022 to 1.68 trillion KRW in fiscal year 2024, 0.9% a year on average. GC Biopharma reports about 2,111 full-time employees.
What stands out
- It reported a net loss in each of its last 2 fiscal years (2023 to 2024), after a profit of 65.45 billion KRW in fiscal year 2022.
Figures from company filings; latest fiscal year ended December 31, 2024.
About GC Biopharma Corp.
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; and Varicella Vaccin. It has a research and development agreement with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.
Largest shareholders
- Gc Corp.50.06%
- National Pension Service of Korea6.67%
- Gc Biopharma Corp.2.34%
- Il-Sup Huh0.5662 %0.57%
- Mok Am Science Scholarship Foundation0.44%
Share of the company, as of September 25, 2026
Leadership
- Eun-chul Huh — CEO, President & Chairman, 53
- Young Sup Huh — Executive Vice President, 84
- Woong Shin M.S. — Head of Operations Division & Director
- Sean Zam — Head of Sales & Marketing
- In-Jae Lee — Senior MD, 62
In the news
- Chicken Pox Market Analysis and Forecast 2025-2035 | Varicella Vaccine Demand Soars as Global Health Initiatives Expand
- Green Cross Health Limited (NZSE:GXH) insiders have significant skin in the game with 37% ownership
- GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology
- GC Biopharma Receives WHO Pre-Qualification for BARYCELA
How much revenue does GC Biopharma make?
GC Biopharma reported 1.68 trillion KRW in revenue for fiscal year 2024, up 3.3% from 1.63 trillion KRW in fiscal year 2023. In Q2 2025 revenue was 500.26 billion KRW.
What is GC Biopharma's largest business segment?
Manufacturing and Sales of Pharmaceuticals, Etc., with 1.98 trillion KRW or 91% of segment revenue in fiscal year 2025. Next: Diagnosis and Analysis of Samples, Etc. (8%) and Other (1%).
Where does GC Biopharma make most of its revenue?
South Korea: 71% of revenue by region in fiscal year 2025, followed by Overseas (29%).
What companies are similar to GC Biopharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hugel, Inc. (145020.KQ), OliX Pharmaceuticals, Inc (226950.KQ), Celltrion Pharm, Inc. (068760.KQ), Daewoong Pharmaceutical Co., Ltd (069620.KS).
Has GC Biopharma made a profit in recent years?
Net income by fiscal year: FY2021, 123.21 billion KRW; FY2022, 65.45 billion KRW; FY2023, a loss of 26.63 billion KRW; FY2024, a loss of 26.28 billion KRW. It reported a net loss in 2 of these 4 years.
Company Information
Data as of .
How to cite: DataPorium, “GC Biopharma Corp. (006280.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/006280.KS